Cardiogenic cerebral infarction is standardized as cardiogenic cerebral embolism, which refers to the dislodgement of thrombus attached to the walls of atria and ventricles, and heart valve redundancy, etc., which enters into the cerebral artery with the bloodstream, resulting in stenosis or acute occlusion of blood vessels, leading to ischemia and necrosis of the cerebral tissues in the cerebrovascular disease, which is commonly seen in atrial fibrillation and congenital heart diseases, such as congenital foramen ovale inoperation.
Patients with atrial fibrillation are prone to thrombus formation in the left auricular region, and thrombus dislodgement can pass through the left atrium to the left ventricle, from the left ventricle to the aorta, and then through the carotid artery into the brain, resulting in cerebral infarction, and the patent foramen ovale is prone to right-to-left shunt, and the thrombus in the circulation can directly pass through the patent foramen ovale into the left ventricle, and then into the cerebral arteries, resulting in cerebral infarction.
Cardiogenic cerebral embolism can be manifested as transient consciousness disorder, headache, dizziness, nausea, vomiting, paralysis of lateral limbs, hemiplegia, etc.; patients should apply thrombolytic and anticoagulant medications in time, such as recombinant tissue-type activator of fibrinolytic enzymes, warfarin, rivaroxaban, aspirin, etc., to avoid patients from experiencing greater damage.
Patients with cardiogenic cerebral embolism should seek medical treatment in time and follow the doctor’s instructions, and should not blindly use medication on their own.